Weekly roundup: June kickstarts with an abundance of appointments
iOnctura bolsters leadership team with new appointments
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, announces the appointments of Steven Sciuto as Chief Financial Officer and Michelle Tsai PharmD as Chief Operating Officer.
Amber Implants announces successful one-year follow-up data in first-in-human clinical of VCFix® Spinal System
Amber Implants announced completion of the one-year follow-up for all patients enrolled in its first-in-human clinical trial of the VCFix® Spinal System. This milestone marks a significant step in demonstrating the safety of VCFix® for the treatment of vertebral compression fractures. The data also showed significant improvements in key performance outcomes, underscoring the system’s promising clinical potential.
Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy
Asgard Therapeutics announces the appointments of Dr Cristina Csimma as an independent member of its Board of Directors, and Prof Ignacio Melero and Prof Brian Brown to its Clinical and Scientific Advisory Board. The appointments mark a significant step on Asgard’s transition to a drug development company, as it advances its lead asset AT-108 towards clinical trials.
Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Commit Biologics announces the formation of its Scientific Advisory Board (SAB) with the appointment of five leading industry and scientific experts. Leading antibody expert Janine Schuurman will co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen. Further appointments to the SAB include: Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel.
Freya Biosciences featured in Bloomberg’s latest newsletter
Colleen Acosta, CEO of Freya Biosciences, recently spoke to Ashleigh Furlong, health reporter at Bloomberg, for Bloomberg’s latest edition of the Prognosis newsletter, spotlighting the evolving landscape of women’s health and how Freya is leading the way with its innovative pipeline of microbial immunotherapy candidates targeting dysbiotic vaginal microbiota.
📺Optimum TV
👥 Industry events
Optimum’s 17th Annual Healthcare Conference
Returning to the King’s Fund this autumn, this prestigious invitation-only event brings together investors and executives from across the life sciences sector, register your interest today.
🚀 Sector moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
